PubMed دسترسی آزاد

Elranatamab: A novel B-cell maturation T-cell engager.

Shahrier Hossain, Giada Bianchi• 2026• Human vaccines & immunotherapeutics

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.

خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…

تنظیم صدای طبیعی و سرعت

صدای فارسی صدای انگلیسی سرعت خواندن

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

B-cell maturation antigen (BCMA) is a highly expressed transmembrane receptor on malignant plasma cells, mediating cell survival. These characteristics make it an attractive target for novel cellular and immunotherapies. Elranatamab is a bispecific antibody targeting BCMA on plasma cells and CD3 on T cells. This leads to immune cell activation and the release of granzymes and perforins, with attendant killing of target cells. Overactivation of the immune system can lead to cytokine release syndrome (CRS) and immune cell associated neurotoxicity syndrome (ICANS). Compared to similar agents, elranatamab has a favorable safety profile with robust efficacy. It is currently approved for relapsed/refractory multiple myeloma with clinical trials evaluating its use in combination and in earlier lines of therapy.

متن کامل اصلی

نسخه دارای مجوز در منبع علمی در دسترس است.

لینک مستقیم از metadata منبع گرفته شده و در تب جدید باز می‌شود.

باز کردن متن کامل

کلیدواژه‌ها

B-cell maturation antigenElranatamabal-amyloidosisbispecific monoclonal antibodiesmultiple myelomaplasma cells

در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Dynamic evolution, prediction and patient stratification of chemotherapy-induced neutropenia in a predominantly breast cancer cohort: A decision-support study for building a bundle care strategy.

BACKGROUND: Chemotherapy-induced neutropenia (CIN) is a common dose-limiting toxicity in patients with solid tumors, often leading to infections, treatment delays, or dose reductions. However, studies on the dynamic patterns of CIN across multiple chemotherapy cycles and their prediction remain limited. OBJECTIVES: To longitudinally observe CIN evolution across two consecutive cycles, develop a predictive model for severe CIN in cycle …

PubMed2026

Amyloid-Like Immunoglobulin Deposition Neuropathy.

BACKGROUND AND AIMS: Amyloid-like immunoglobulin deposition neuropathy is a rare cause of polyneuropathy, characterised by unique clinical and histological features in combination with proteomics that distinguish it from both amyloidosis and anti-MAG neuropathy. While light microscopic findings resemble amyloidosis with 'amyloid-like deposits', they are negative for Congo-red stain and have granular ultrastructure appearances under ele…

PubMed2026

Research trends and hotspots of CAR-T cell therapy for acute lymphoblastic leukemia: A bibliometric analysis.

This study aims to analyze the global research patterns and emerging trends in CAR-T cell therapy for ALL through a bibliometric analysis. Publications were retrieved from the Web of Science Core Collection database. The bibliometric analysis utilized VOSviewer, CiteSpace, and the R package "bibliometrix" to visualize collaborations, keyword co-occurrences, and emerging research trends. A total of 844 articles from 253 journals by 6,45…

PubMed2026

Benralizumab effectiveness in a real-world Portuguese severe eosinophilic asthma population: BETREAT study.

BACKGROUND AND OBJECTIVES: Severe eosinophilic asthma (SEA) is often inadequately controlled. The BETREAT study evaluated the real-world effectiveness of benralizumab, an anti-IL-5 receptor monoclonal antibody, in Portugal, focusing on treatment persistence, asthma control, exacerbation rates, and quality of life (QoL). STUDY DESIGN AND METHODS: Retrospective, observational study including SEA adults who received benralizumab between J…